Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (NCT06922591)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
🩺 Plain-English Summary (8th-Grade Level)
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Scottsdale — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Mayo Clinic Scottsdale — Scottsdale, Arizona
- Sarah Cannon Research Institute Denver — Denver, Colorado
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Indiana — Indianapolis, Indiana
- University of Iowa Health Care — Iowa City, Iowa
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Cancer Center — Rochester, Minnesota
- Nebraska Cancer Specialists — Omaha, Nebraska
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- NEXT Oncology — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (857) 320-4899
Email: clinicaltrials@tangotx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All PDAC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.